+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Brain Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Brain Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011104
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The brain cancer drugs market continues to undergo rapid transformation, with innovation in molecular diagnostics and therapies shaping competitive dynamics and patient care standards. Senior decision-makers must remain agile, reexamining their approaches to sustain leadership in an evolving landscape.

Market Snapshot: Brain Cancer Drugs Market

The brain cancer drugs market expanded from USD 2.34 billion in 2025 to USD 2.51 billion in 2026, demonstrating ongoing momentum. The sector is projected to maintain a compound annual growth rate (CAGR) of 7.66%, reaching a market value of USD 3.93 billion by 2032. Continued innovation, coupled with changes in regulation and patient access models, underpins this growth trajectory in major global regions.

Scope & Segmentation

  • Tumor Types: Primary brain tumors—including glioblastoma multiforme, metastatic tumors, meningiomas, and pituitary tumors—are distinguished by distinct biological features and management challenges.
  • Therapeutic Classes: The market covers chemotherapy agents (such as alkylating agents, antimetabolites, and plant alkaloids), targeted therapies (monoclonal antibodies and tyrosine kinase inhibitors), immunotherapies (cancer vaccines, checkpoint inhibitors, CAR-T therapies), and supporting treatments for managing symptoms and complications.
  • Drug Delivery Technologies: Innovation spans intrathecal, intravenous, oral, and localized administration approaches. Advanced delivery technologies are crucial for overcoming the blood-brain barrier and achieving effective central nervous system drug concentrations.
  • End Users: Care is delivered through clinics, hospitals, and home healthcare providers, each shaping treatment pathways and access to brain cancer drugs.
  • Distribution Channels: Medicines are supplied through hospital pharmacies, online and retail pharmacies, influencing the reach and convenience of therapy distribution.
  • Regions: The market comprises the Americas, Europe Middle East & Africa, and Asia-Pacific. Each region presents unique regulatory frameworks, infrastructure capabilities, and commercialization approaches, impacting strategy and execution.

Brain Cancer Drugs Market: Key Takeaways

  • Molecular diagnostics and advanced imaging are changing patient stratification and enhancing the personalization of therapeutic decisions. These advances enable improved identification of target populations and therapy matching.
  • Emerging delivery solutions, combined with digital health tools, support expanded patient enrollment into clinical trials and offer better mechanisms for monitoring outcomes over the long term.
  • Collaboration is increasing among biotechnology firms, pharmaceutical companies, academic medical centers, and contract service providers. These partnerships help accelerate research, distribute development risks, and strengthen the supporting evidence base for new brain cancer drugs.
  • Regulatory agencies and payers are placing greater emphasis on patient-centric endpoints, such as neurocognitive function and overall quality of life, increasingly shaping approval and reimbursement requirements.
  • Sustained commercial success requires tight integration between clinical innovation, operational execution, and go-to-market planning tailored for disparate health systems.

Tariff Impact: United States 2025 Tariff Changes

Recent changes in United States tariff policies for 2025 prompted manufacturers to revisit sourcing and procurement for brain cancer therapeutics. Industry stakeholders have diversified their supply chains and made targeted investments in regional manufacturing to manage cost fluctuations. This shift has downstream impacts on access planning, contract negotiation, and reimbursement strategies, leading payers and procurement teams to more closely examine holistic cost and value structures.

Methodology & Data Sources

This research employs a multi-source methodology, using structured interviews with international experts, comprehensive literature reviews, and regulatory analyses. Comparative analytics are applied across therapies, delivery technologies, and end user segments. Transparent methods and well-documented criteria ensure findings are actionable for high-level decision-making. Appendices provide further customization options to support specific strategic needs.

Why This Report Matters

  • Enables executive teams to benchmark against market innovation, regional access strategies, and emerging partnership models in the brain cancer drugs market.
  • Clarifies technological and segmentation trends to inform investment prioritization and new product development.
  • Delivers concise analysis of global industry shifts, regulatory variation, and procurement patterns, supporting effective planning for regional and international market entry.

Conclusion

Delivering effective brain cancer therapies requires the alignment of scientific discovery, operational agility, and adaptive commercialization. Organizations that implement resilient, integrated strategies are positioned to realize significant patient and market value as the industry evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Brain Cancer Drugs Market, by Indication
8.1. Glioblastoma Multiforme
8.2. Meningioma
8.3. Metastatic Brain Tumors
8.4. Pituitary Tumors
9. Brain Cancer Drugs Market, by Drug Class
9.1. Chemotherapy
9.1.1. Alkylating Agents
9.1.2. Antimetabolites
9.1.3. Plant Alkaloids
9.2. Immunotherapy
9.2.1. Cancer Vaccines
9.2.2. CAR-T Therapy
9.2.3. Checkpoint Inhibitors
9.3. Supportive Therapy
9.3.1. Anti-Emetics
9.3.2. Growth Factors
9.4. Targeted Therapy
9.4.1. Monoclonal Antibodies
9.4.2. Tyrosine Kinase Inhibitors
10. Brain Cancer Drugs Market, by Route Of Administration
10.1. Intrathecal
10.2. Intravenous
10.3. Oral
11. Brain Cancer Drugs Market, by End User
11.1. Clinics
11.2. Home Healthcare
11.3. Hospitals
12. Brain Cancer Drugs Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Brain Cancer Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Brain Cancer Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Brain Cancer Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Brain Cancer Drugs Market
17. China Brain Cancer Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. Arbor Pharmaceuticals, LLC
18.8. AstraZeneca PLC
18.9. Bayer AG
18.10. Bristol-Myers Squibb Company
18.11. Celgene Corporation (a Bristol-Myers Squibb company)
18.12. DNAtrix, Inc.
18.13. Eli Lilly and Company
18.14. F. Hoffmann-La Roche Ltd
18.15. Ipsen SA
18.16. Johnson & Johnson
18.17. Karyopharm Therapeutics Inc.
18.18. Kazia Therapeutics Limited
18.19. Merck KGaA
18.20. Mundipharma International Limited
18.21. Novartis AG
18.22. Novocure GmbH
18.23. Pfizer Inc.
18.24. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 137. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 138. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 157. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 158. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 159. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 160. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 177. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 178. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 179. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 180. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 181. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. GCC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. GCC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. GCC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 188. GCC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 189. GCC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 190. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 191. GCC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. GCC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 208. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 209. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 210. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 211. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. G7 BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. G7 BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 216. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. G7 BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 218. G7 BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 219. G7 BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 220. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 221. G7 BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. G7 BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. NATO BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 225. NATO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 226. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 227. NATO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 228. NATO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 229. NATO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 230. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 231. NATO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. NATO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 247. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 248. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 249. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 250. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 251. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 252. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Brain Cancer Drugs market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Arbor Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation (a Bristol-Myers Squibb company)
  • DNAtrix, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ipsen SA
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Merck KGaA
  • Mundipharma International Limited
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.51 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.93 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Brain & Spinal Cord Cancer Market - Global Forecast 2026-2032 - Product Image

Brain & Spinal Cord Cancer Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032 - Product Image

Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Glioblastoma - Pipeline Insight, 2025 - Product Image

Glioblastoma - Pipeline Insight, 2025

  • Clinical Trials
  • 450 Pages
  • Global
From
Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Brain Cancer Drugs Market

The Brain Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat brain cancer. Brain cancer is a type of cancer that affects the cells of the brain and can be caused by a variety of factors, including genetics, environmental exposure, and lifestyle. Brain cancer drugs are used to treat the symptoms of brain cancer, such as headaches, seizures, and nausea, as well as to slow the progression of the disease. Brain cancer drugs are typically divided into two categories: chemotherapy and targeted therapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are designed to target specific cancer cells and stop them from growing. Both types of drugs are used in combination to treat brain cancer. Some of the major companies in the Brain Cancer Drugs market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. These companies are involved in the development and sale of drugs used to treat brain cancer, as well as in the research and development of new treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.